International reference pricing: discounts down under far surpass U.S. drug price concessions

1 September 2020 - At 30,000 feet, the view of Australia’s healthcare system does not look too different from our own ...

Read more →

Direct or indirect comparison: reliance on innovative drug data key to engaging data protection

15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...

Read more →

PBAC asks Roche for another comparison for Tecentriq

20 July 2020 - The submission requested a PBS (Section 100) listing for atezolizumab for use in combination with taxane chemotherapy ...

Read more →

A comparison of the EQ-5D-3L and EQ-5D-5L

12 May 2020 - Previous studies have found the EQ-5D-5L to have superior measurement properties but no study has compared ...

Read more →

Performance of UK National Health Service compared with other high income countries: observational study

27 November 2019 - The UK’s spending on health care has been constrained for some time, with slow growth in spending ...

Read more →

Medicine prices in Australia among the cheapest in the world, research shows

25 November 2019 - If you take medication for several health issues, you may be surprised to find out Australia has ...

Read more →

New Zealand's access to funded medicines 'well behind the rest of the world'

12 August 2019 - New Zealand has the worst access to funded modern medicines of 20 OECD countries, a report ...

Read more →

Bev takes 14 pills a day. She's far from alone.

15 July 2019 - She is among the more than one-in-three Australians aged over 70 who take five or more different ...

Read more →

Population adjustment methods for indirect comparisons: A review of NICE Technology Appraisals

13 June 2019 - Indirect comparisons via a common comparator (anchored comparisons) are commonly used in health technology assessment. However, ...

Read more →

What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.

7 February 2019 - Decisions on the reimbursement of the same cancer drugs are different across European countries, but empirical work ...

Read more →

Comparing PHARMAC's outcomes with those of Australia

7 February 2019 - New Zealand's Prime Minister Jacinda Ahern's claim that is unfair to compare PHARMAC's outcomes with those ...

Read more →

Jacinda Ardern: not fair to compare PHARMAC with Australia's system

5 February 2019 - Jacinda Ardern told The AM Show New Zealand's drug buying agency has "been pointed to as being ...

Read more →

PBAC shows no propensity to support Amgen's innovative method of analysis

12 November 2018 - Amgen's recent submission for blinatumomab (Blincyto) treatment of patients with B-cell precursor acute lymphoblastic leukaemia in haematological ...

Read more →

Outdated public funding model failing New Zealand patients

9 October 2018 - Publicly funded modern medicines are out of reach for many patients in New Zealand according to ...

Read more →

Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?

8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...

Read more →